



DEPARTMENT OF JUSTICE

Statement of

**Christine A. Varney
Assistant Attorney General
Antitrust Division
U.S. Department of Justice**

Before the

**Committee on the Judiciary
United States Senate**

Hearing on

**“Prohibiting Price Fixing and Other Anticompetitive
Conduct in the Health Insurance Industry”**

October 14, 2009

Good morning, Mr. Chairman and members of the Committee. I am pleased to be here today to present the views of the Department of Justice on the Committee's reconsideration of the McCarran-Ferguson Act's antitrust immunity for the business of insurance.

Prior to 1944, regulation of the business of insurance was seen as the exclusive province of the states. In that year, the Supreme Court held in *United States v. South-Eastern Underwriters Association*¹ that the insurance business was within the regulatory power of Congress under the Commerce Clause, and thus was subject to the antitrust laws. This decision was perceived to threaten state authority to regulate and tax the business of insurance. The McCarran-Ferguson Act was designed to return the legal climate to that which existed prior to *South-Eastern Underwriters* by specifically delegating to the states the authority to continue to regulate and tax the business of insurance. It also created a broad antitrust exemption based on state regulation. This antitrust exemption applies where three basic requirements are met: (1) the challenged activity must be part of the "business of insurance," (2) that business must be regulated by state law, and (3) the activity must not constitute boycott, coercion, or intimidation.

Repeal or reform of the broad antitrust exemption currently enjoyed by the business of insurance has been a perennial subject of interest. In 1977, a Justice Department study concluded that the insurance industry could function competitively without the protection of the McCarran-Ferguson Act. The National Commission for the Review of Antitrust Laws and Procedures recommended in 1979 that the broad exemption in the Act be replaced by narrowly drawn legislation adopted to affirm the lawfulness of a limited number of collective activities under the antitrust laws. The 1989

¹ 322 U.S. 533.

report of the American Bar Association Commission to Improve the Liability Insurance System contained a generally similar recommendation.

The Antitrust Modernization Commission recently reviewed whether the McCarran-Ferguson Act is necessary to allow insurers to collect, aggregate, and review data on losses so that they can better set their rates to cover their likely costs. The AMC found that it was not. The AMC said that insurance companies “would bear no greater risk than companies in other industries engaged in data sharing and other collaborative undertakings.” In particular, the AMC said, “[l]ike all potentially beneficial competitor collaboration generally ... such data sharing would be assessed by antitrust enforcers and the courts under a rule of reason analysis that would fully consider the potential procompetitive effects of such conduct and condemn it only if, on balance, it was anticompetitive.”² Significantly, the AMC added that “[t]o the extent that insurance companies engage in anticompetitive collusion ... then they appropriately [should] be subject to antitrust liability.”³

In addition to these reviews, this Committee and other bodies of Congress have held several hearings on the McCarran-Ferguson exemption over the years, and have introduced various bills that would eliminate the current exemption or replace it with a narrower one affording continued protection to certain procompetitive activities. The pros and cons, as well as the particulars, of legislative reform of the McCarran-Ferguson antitrust exemption have thus been thoroughly and carefully debated.

² ANTITRUST MODERNIZATION COMM’N, REPORT AND RECOMMENDATIONS 351 (2007) (footnotes omitted), *available at* http://govinfo.library.unt.edu/amc/report_recommendation/amc_final_report.pdf.

³ The American Bar Association of Antitrust Law shares these views, concluding recently that the “historic justification for the McCarran-Ferguson Act’s antitrust exemption appears to have lost most or all of its former appeal.” SECTION OF ANTITRUST LAW, AM. BAR ASS’N, FEDERAL STATUTORY EXEMPTIONS FROM ANTITRUST LAW 159 (2007).

The Department is generally opposed to exemptions from the antitrust laws, whether they be industry-specific or general, in the absence of a strong showing of a compelling need. The antitrust laws reflect our society's belief that competition enhances consumer welfare and promotes our economic and political freedoms. Exceptions from that policy should be—and fortunately are—relatively rare. Those who advocate the creation of a new antitrust exemption, or the preservation of a longstanding exemption such as that contained in the McCarran-Ferguson Act, rightfully bear a heavy burden in justifying the exemption.

The exemption has been subject to criticism as to its results. One antitrust treatise notes that under the McCarran-Ferguson Act “the presence of even minimal state regulation, even on an issue unrelated to the antitrust suit, is generally sufficient to preserve the immunity.”⁴ Indeed, the case law can be read as suggesting that the Act precludes federal antitrust action whenever there is a state regulatory scheme, regardless of how perfunctory or ineffective it may be.⁵ It is fair to say that the McCarran-Ferguson Act antitrust exemption is very expansive with regard to anything that can be said to fall within “the business of insurance,” including premium pricing and market allocations. As a result, “the most egregiously anticompetitive claims, such as naked agreements fixing price or reducing coverage, are virtually always found immune.”⁶

Concerns over the exemption's effects are especially relevant given the importance of health insurance reform to our nation. There is a general consensus that health insurance reform should be built on a strong commitment to competition in all health care markets, including those for health and medical malpractice insurance.

⁴ 1A PHILLIP E. AREEDA & HERBERT HOVENKAMP, ANTITRUST LAW ¶ 219c, at 25 (3d ed. 2006).

⁵ See, e.g., *Ohio AFL-CIO v. Insurance Rating Board*, 451 F.2d 1178 (6th Cir. 1971).

⁶ AREEDA & HOVENKAMP, *supra* note 2, ¶ 219d, at 31.

Repealing the McCarran-Ferguson Act would allow competition to have a greater role in reforming health and medical malpractice insurance markets than would otherwise be the case.

In considering any alleged need for an antitrust exemption, the flexible nature of the antitrust laws as interpreted in such recent cases as *General Dynamics*,⁷ *GTE Sylvania*,⁸ *Broadcast Music*,⁹ *Northwest Wholesale Stationers*,¹⁰ and *Dagher*¹¹ must be recognized. Allegations that particular procompetitive behavior would violate the antitrust laws and thus should be exempted from their application can fail to take account of the economically sound competitive analysis that is used today to carefully circumscribe *per se* rules and fully analyze other conduct under the rule of reason. Congress has occasionally recognized a need for clarification of a proper antitrust standard or adjustment of antitrust remedies, but the flexibility of the antitrust laws and their crucial importance to the economy argue strongly against antitrust exemptions that are not clearly and convincingly justified.

There are strong indications that possible justifications for the broad insurance antitrust exemption in the McCarran-Ferguson Act when it was enacted in 1945 are no longer valid today. To the extent that the exemption was designed to enable the states to continue to regulate the business of insurance, it is no longer necessary. The “state action” defense, which had been announced by the Supreme Court in *Parker v. Brown*¹² in 1943, but was undeveloped in 1945 when the McCarran-Ferguson Act was enacted,

⁷ United States v. General Dynamics Corp., 415 U.S. 486 (1974).

⁸ Continental T.V., Inc. v. GTE Sylvania, Inc., 433 U.S. 36 (1977).

⁹ Broadcast Music, Inc. v. Columbia Broadcasting Sys., Inc., 441 U.S. 1 (1979).

¹⁰ Northwest Wholesale Stationers, Inc. v. Pacific Stationary and Printing Co., 472 U.S. 284 (1985).

¹¹ Texaco Inc. v. Dagher, 547 U.S. 1 (2006).

¹² 317 U.S. 341.

has now been the subject of many Supreme Court opinions. This defense allows a state effectively to immunize what the antitrust laws otherwise may proscribe by clearly articulating and affirmatively expressing a policy to displace competition, and by actively supervising any private conduct that might be involved.

Moreover, the application of the antitrust laws to potentially procompetitive collective activity has become far more sophisticated during the 62 years since the McCarran-Ferguson Act was enacted. Some forms of joint activity that might have been prohibited under earlier, more restrictive doctrines are now clearly permissible, or at very least analyzed under a rule of reason that takes appropriate account of the circumstances and efficient operation of a particular industry. Thus, there is far less reason for concern that overly restrictive antitrust rulings would impair the insurance industry's efficiency.

In sum, the Department of Justice generally supports the idea of repealing antitrust exemptions. However, we take no position as to how and when Congress should address this issue. In conjunction with the Administration's efforts to strengthen insurance regulation and states' role in setting and enforcing policies, the Department supports efforts to bring more competition to the health insurance marketplace that lower costs, expand choice, and improve quality for families, businesses, and government. As you know, the Administration has been working with the Congress to enact health care reform that lowers costs and offers affordable coverage to all Americans. Yesterday, the Senate Finance Committee became the fifth and final committee to report out a health reform bill. The President has said that these reforms "would greatly benefit Americans from all walks of life, as well as the economy as a whole." We know that you share this

goal, and we look forward to working with you and your colleagues in achieving our common objectives.

Mr. Chairman, this concludes my prepared statement. I would be happy to address any questions that you or the other members of the Committee may have.